10x Genomics, Inc. logo TXG - 10x Genomics, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 10
HOLD 11
SELL 1
STRONG
SELL
0
| PRICE TARGET: $22.43 DETAILS
HIGH: $30.00
LOW: $17.00
MEDIAN: $22.00
CONSENSUS: $22.43
DOWNSIDE: 5.28%
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue
Revenue 642.8 610.8 618.7 516.4 490.5 298.8 245.9 146.3 71.1
Cost of Revenue 198.9 196.3 209.4 120.4 74.1 58.5 61.0 28.7 10.6
Gross Profit 443.9 414.5 409.3 396.0 416.4 240.4 184.9 117.7 60.5
Operating Expenses
R&D Expenses 238.6 264.7 270.3 265.7 211.8 123.4 83.1 47.5 32.2
SG&A Expenses 316.1 344.3 343.3 298.3 257.6 202.3 130.8 87.9 46.7
Other Expenses 0 0 61.0 0 0 0 0 (0.2) 0.1
Operating Expenses 554.8 609.0 674.6 564.0 469.3 325.7 213.9 135.5 78.9
Operating Income
Operating Income (110.9) (194.6) (265.3) (167.9) (52.9) (85.3) (29.1) (110.8) (18.4)
Interest Expense 0 0.0 0.0 0.5 0.9 1.7 3.1 2.4 0.8
Interest Income 20.0 18.4 16.9 6.6 0.2 1.5 2.8 1.0 0.3
Profitability
EBITDA (110.9) (134.0) (205.1) (128.5) (24.6) (513.8) (20.9) (106.1) (13.6)
EBIT (110.9) (177.7) (248.7) (161.5) (52.8) (532.8) (28.0) (110.0) (17.9)
Income Before Tax (39.9) (177.7) (248.8) (162.0) (53.7) (534.5) (31.0) (112.4) (18.7)
Income Tax Expense 3.6 4.9 6.3 4.0 4.5 8.3 0.2 0.1 0.0
Net Income (43.5) (182.6) (255.1) (166) (58.2) (542.7) (31.3) (112.5) (18.8)
Per Share Data
EPS (Basic) -0.35 -1.52 -2.18 -1.46 -0.53 -5.37 -0.80 -8.40 -1.62
EPS (Diluted) -0.35 -1.52 -2.18 -1.46 -0.53 -5.37 -0.80 -8.40 -1.62
Shares Outstanding 124.7 120.5 117.2 113.9 110.3 101.2 39.1 13.4 11.6
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Current Assets
Cash & Cash Equivalents 474.0 344.1 359.3 219.7 587.4 663.6 424.2 65.1 47.9
Short-Term Investments 49.4 49.3 29.4 210.2 0 0 0 0 0
Net Receivables 82.5 87.9 114.8 104.2 85.3 51.2 33.4 28.1 13.3
Inventory 56.3 83.1 73.7 81.6 60.0 30.0 15.3 8.6 4.8
Other Current Assets 22.2 20.0 18.8 19.2 1.0 16.6 0 0 2.1
Total Current Assets 684.5 584.4 596.0 635.0 747.6 774.4 480.8 106.2 68.1
Non-Current Assets
Property, Plant & Equipment 287.2 309.9 344.9 359.2 230.4 119.8 48.8 11.1 6.9
Goodwill 4.5 4.5 4.5 4.5 4.5 0 0 0 0
Intangible Assets 62.3 15.7 16.6 22.9 25.4 22.4 22.4 0 0
Long-Term Investments 0 0 0 0 0 0 0 5.0 0
Other Non-Current Assets 2.9 4.1 3.1 7.4 10.9 12.8 53.9 1.9 0.6
Total Non-Current Assets 356.9 334.2 369.1 393.9 271.2 155.0 125.1 18.1 7.5
Total Assets 1,041.4 918.6 965.1 1,029.0 1,018.8 929.3 605.9 124.3 75.6
Current Liabilities
Account Payables 12.7 12.9 15.7 21.6 17.4 4.7 13.0 8.8 5.4
Short-Term Debt 11.0 0 0 0 0 0 9.9 4.2 4.2
Deferred Revenue 23.9 20.7 13.2 7.9 5.3 6.2 4.6 2.8 1.8
Other Current Liabilities 63.3 41.8 34.0 29.7 40.9 21.6 15.6 9.2 6.7
Total Current Liabilities 153.5 117.6 127.2 131.0 110.4 118.1 63.0 32.4 22.1
Non-Current Liabilities
Long-Term Debt 73.4 0 0 0 0 0 19.8 25.5 6.3
Deferred Tax Liabilities 0 0 0 0 0 0 0 284.6 158.4
Other Non-Current Liabilities (65.7) 5.0 4.3 3.0 14.1 15.1 102.1 0.8 0.5
Total Non-Current Liabilities 91.6 90.9 96.9 92.3 90.9 72.1 122.8 311.9 166.0
Total Liabilities 245.0 208.5 224.1 223.2 201.3 190.3 185.8 344.3 188.1
Stockholders' Equity
Common Stock 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Retained Earnings (1,510.6) (1,467.0) (1,284.4) (1,029.3) (863.3) (805.1) (262.4) (231.1) (118.6)
Accumulated Other Comprehensive Income 0.2 (0.5) (0.4) (4.3) 0.0 (0.1) (0.0) (0.0) (0.0)
Total Stockholders' Equity 796.3 710.1 741.0 805.7 817.6 739.1 420.1 (220.0) (112.5)
Total Liabilities & Equity 1,041.4 918.6 965.1 1,029.0 1,018.8 929.3 605.9 124.3 75.6
Debt Metrics
Total Debt 157.7 82.6 95.4 95.2 82.0 63.0 29.7 29.7 10.6
Net Debt (316.2) (261.5) (263.9) (124.6) (505.5) (600.6) (394.4) (35.4) (37.3)
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Operating Activities
Net Income (43.5) (182.6) (255.1) (166) (58.2) (542.7) (31.3) (112.5) (18.8)
Depreciation & Amortization 43.8 43.7 43.6 33.0 28.3 19.0 7.1 3.9 4.3
Stock-Based Compensation 109.1 140.7 166.9 136.8 96.0 48.6 13.3 2.7 1.7
Change in Working Capital 24.9 1.3 17.3 (39.4) (87.4) (50.4) 44.8 28.0 1.9
Other Non-Cash Items 1.7 3.6 12.0 2.0 0.1 306.0 0.1 1.2 0.1
Operating Cash Flow 136.1 6.7 (15.2) (33.6) (21.4) (217.9) 34.6 (76.4) (10.7)
Investing Activities
Capital Expenditure (5.9) (12.4) (49.5) (131.7) (101.3) (38.4) (42.8) (6.7) (3.8)
Acquisitions (9.3) 0 0 (4) (5.5) 0 0 0 0
Purchases of Investments (123.4) (48.9) 0 (282.9) 0 0 0 0 0
Sales/Maturities of Investments 125.2 29.6 183.0 67.6 0 0 0 0 0
Other Investing Activities 0 (1) (0.9) 0 0 0 0 (0.4) 0
Investing Cash Flow (13.4) (32.6) 133.5 (350.9) (106.7) (38.4) (42.8) (6.7) (3.8)
Financing Activities
Net Debt Issuance 0 0 (5.8) (5.4) (5.0) (37.1) 0 18.7 (0.4)
Stock Repurchased 0 0 0 0 0 0 0 0 (0.1)
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 0 0 0 0 23.7 3.8 1.8 1.1
Financing Cash Flow 6.8 10.9 13.7 15.8 35.3 468.9 414.6 105.4 20.6
Cash Position
Net Change in Cash 129.9 (15.2) 131.9 (368.7) (92.6) 212.2 406.4 22.2 6.1
Cash at Beginning 344.1 359.3 227.4 596.1 688.6 476.5 70.1 47.9 41.7
Cash at End 474.0 344.1 359.3 227.4 596.1 688.6 476.5 70.1 47.9
Free Cash Flow 130.1 (5.7) (64.7) (165.3) (122.7) (256.3) (8.1) (83.1) (14.5)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017
Income Statement
Revenue 642.8 610.8 618.7 516.4 490.5 298.8 245.9 146.3 71.1
Gross Profit 443.9 414.5 409.3 396.0 416.4 240.4 184.9 117.7 60.5
Operating Income (110.9) (194.6) (265.3) (167.9) (52.9) (85.3) (29.1) (110.8) (18.4)
Net Income (43.5) (182.6) (255.1) (166) (58.2) (542.7) (31.3) (112.5) (18.8)
EPS (Diluted) -0.35 -1.52 -2.18 -1.46 -0.53 -5.37 -0.80 -8.40 -1.62
Balance Sheet
Cash & Equivalents 474.0 344.1 359.3 219.7 587.4 663.6 424.2 65.1 47.9
Total Assets 1,041.4 918.6 965.1 1,029.0 1,018.8 929.3 605.9 124.3 75.6
Total Debt 157.7 82.6 95.4 95.2 82.0 63.0 29.7 29.7 10.6
Stockholders' Equity 796.3 710.1 741.0 805.7 817.6 739.1 420.1 (220.0) (112.5)
Cash Flow
Operating Cash Flow 136.1 6.7 (15.2) (33.6) (21.4) (217.9) 34.6 (76.4) (10.7)
Capital Expenditure (5.9) (12.4) (49.5) (131.7) (101.3) (38.4) (42.8) (6.7) (3.8)
Free Cash Flow 130.1 (5.7) (64.7) (165.3) (122.7) (256.3) (8.1) (83.1) (14.5)